

Addressing data deficiency in ADME predictive modeling

Markus Orsi, University of Bern

Bringing a new medicine to patients is a complex challenge, where success relies on balancing high drug efficacy with a strong safety profile. At Roche, we are actively developing machine learning models that help us identify potential issues much earlier in the research timeline, avoiding wasted effort in the later, more expensive stages of drug development.

I'll discuss why these models are so important and where the technology stands today. I will also address our biggest challenge: data scarcity. You'll learn how we tackle this by using data from different sources, allowing us to improve model performance even when information is limited.